An Open-Label Trial of Vesicare (Solifenacin Succinate) for the Treatment of Diarrhea Predominant Irritable Bowel Syndrome (IBS-D).

Trial Profile

An Open-Label Trial of Vesicare (Solifenacin Succinate) for the Treatment of Diarrhea Predominant Irritable Bowel Syndrome (IBS-D).

Completed
Phase of Trial: Phase II

Latest Information Update: 22 Mar 2012

At a glance

  • Drugs Solifenacin (Primary)
  • Indications Irritable bowel syndrome
  • Focus Therapeutic Use
  • Most Recent Events

    • 22 Mar 2012 Status changed from active, no longer recruiting to completed as reported by University Hospital Medical Information Network - Japan.
    • 22 Mar 2012 Actual end date (Oct 2011) added as reported by University Hospital Medical Information Network - Japan.
    • 10 May 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top